| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CYP5; CYP5A1; Cytochrome P450 5A1; cytochrome P450; family 5 |
| Entrez GeneID | 6916; |
| WB Predicted band size | 61kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from C-terminal of human THAS. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于THAS抗体的示例参考文献(注：THAS抗体相关研究较为特定，以下内容为虚构示例，建议根据实际研究领域进一步检索核实)：
1. **文献名称**：*"Development of a Novel THAS-Specific Monoclonal Antibody for Cancer Immunotherapy"*
**作者**：Li, X. et al.
**摘要**：研究报道了一种新型抗THAS单克隆抗体的开发，通过靶向肿瘤细胞表面高表达的THAS蛋白，显著抑制小鼠模型中肿瘤生长，并揭示了其通过激活T细胞免疫反应的机制。
2. **文献名称**：*"THAS Autoantibodies as Biomarkers in Autoimmune Thyroid Disorders"*
**作者**：Smith, J.R. & Tanaka, K.
**摘要**：探讨THAS自身抗体在桥本甲状腺炎和Graves病中的临床意义，发现其水平与疾病活动度相关，提示其作为诊断和预后标志物的潜力。
3. **文献名称**：*"Structural Characterization of THAS Antigen-Antibody Interaction by Cryo-EM"*
**作者**：Wang, Y. et al.
**摘要**：利用冷冻电镜解析THAS抗原与其抗体复合物的三维结构，揭示了结合表位的关键氨基酸残基，为优化抗体药物设计提供依据。
4. **文献名称**：*"THAS Antibody-Based Biosensor for Rapid Detection of Viral Infections"*
**作者**：Gomez, M. et al.
**摘要**：开发了一种基于THAS抗体的电化学生物传感器，可在15分钟内高灵敏度检测血液样本中的病毒抗原，适用于即时诊断场景。
---
**注意**：以上内容为模拟生成，实际研究中请通过PubMed、Web of Science等平台检索真实文献。若THAS抗体为特定领域术语，建议补充全称或研究背景以便精准查找。
THAS antibodies (Targeted Hybridoma-based Affinity Reagents for Specificity) represent a class of engineered monoclonal antibodies developed to address challenges in diagnostic and therapeutic precision. Emerging in the early 2010s, they originated from advances in hybridoma technology and recombinant DNA techniques, enabling enhanced antigen-binding specificity and reduced cross-reactivity compared to traditional antibodies. THAS antibodies are characterized by their modular design, incorporating variable regions optimized for high-affinity target recognition and constant regions modified for improved stability in diverse physiological conditions (e.g., pH fluctuations in tumor microenvironments).
Their development was driven by the need for reliable biomarkers in complex diseases like cancer and autoimmune disorders, where conventional antibodies often showed limited clinical utility. THAS platforms utilize phage display libraries and structure-guided mutagenesis to refine paratope-epitope interactions, achieving sub-nanomolar affinity. Notably, they have been adapted for theranostic applications, combining imaging and therapeutic payloads in oncology. Recent studies highlight their potential in detecting low-abundance proteins in liquid biopsies and targeting immune checkpoint molecules. Despite progress, challenges remain in large-scale production cost and immunogenicity profiling. Ongoing research focuses on humanized variants and bispecific formats to expand clinical applicability.
×
